Back to results
US 8,012,477 B2Granted
Methods of treating multiple myeloma using IL-17 binding molecules
AssigneesNovartis AG, Novartis Pharma AG
InventorsMichael Cooreman, Franco E. Di Padova
Life of this patent
Estimating the term…
Abstract
An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of a solid or hematological malignant diseases.
Claims6
A method of treating multiple myeloma, comprising administering to a patient in need thereof a therapeutically effective amount of an IL-17 antibody or antigen binding fragment thereof comprising:
- a. a heavy (VH) chain variable domain comprising the amino acid sequence set forth as SEQ ID NO:8;
- b. a light (VL) chain variable domain comprising the amino acid sequence set forth as SEQ ID NO:10;
- c. a heavy (VH) chain variable domain comprising the amino acid sequence set forth as SEQ ID NO:8 and a light (VL) chain variable domain comprising the amino acid sequence set forth as SEQ ID NO:10;
- or
- d. the three Complementarity-Determining Regions (CDRs) of the amino acid sequence set forth as SEQ ID NO:8 and the three CDRs of the amino acid sequence set forth as SEQ ID NO:10.
2 more elements
Dependencies are inferred from the claim text.